Exact Sciences Gets Medicare Reimbursement, Pursues Private Insurers
Summary
Exact Sciences Gets Medicare Reimbursement, Pursues Private Insurers Xconomy Wisconsin — In another important step for Exact Sciences, the Madison, WI-based company said today that the Centers for Medicare & Medicaid Services (CMS) will reimburse the use of its colon cancer diagnostic at $502 per test.CMS had previously announced it would cover the test for Medicare patients, but the reimbursement rate wasn’t confirmed until today.The company intends to negotiate with private insurers to reimburse the test at a higher rate than Medicare, Exact CEO Kevin Conroy told Xconomy.The cancer is treatable when detected early, but an estimated 23 million Americans between the ages of 50 and 75 aren’t getting screened as recommended by healthcare providers, Exact says.Over the past few months, Exact has embarked on an aggressive sales and marketing campaign for Cologuard that has yielded some early traction among doctors and healthcare systems—and shot the company’s stock to its all-time high in October.
Classifications
AskAI Classifications
LabelsLinked Companies
